Evidence map›Paper›PMID 38542402›Full record

ArticleInternational journal of molecular sciences2024

Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology.

Diána Simon, Dorottya Kacsándi, Anita Pusztai, Boglárka Soós, Edit Végh, György Kerekes, Monika Bodoki, Szilvia Szamosi, Gabriella Szűcs, Zoltán Prohászka and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Diána SimonDepartment of Immunology and Biotechnology, Clinical Center, University of Pécs Medical School, 7624 Pécs, Hungary.
Dorottya KacsándiDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Anita PusztaiDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Boglárka SoósDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Edit VéghDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
György KerekesIntensive Care Unit, Department of Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Monika BodokiDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Szilvia SzamosiDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Gabriella SzűcsDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Zoltán ProhászkaResearch Laboratory, Department of Medicine and Hematology, Semmelweis University, 1125 Budapest, Hungary.
Péter NémethDepartment of Immunology and Biotechnology, Clinical Center, University of Pécs Medical School, 7624 Pécs, Hungary.ORCID 0000-0002-3406-2010
Tímea BerkiDepartment of Immunology and Biotechnology, Clinical Center, University of Pécs Medical School, 7624 Pécs, Hungary.
Zoltán SzekaneczDepartment of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0002-7794-6844
University of Debrecen · HUUniversity of Pecs · HUSemmelweis University · HU

Funding

European Union EGA-10European Union GINOP-2.3.2-15-2016-00050European Union TAMOP-4.2.4.A/2-11/1-2012-0001Pfizer (United Kingdom) WS1695414
6 · The paper itself

Abstract

Cardiovascular (CV) morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Natural autoantibodies (nAAb) are involved in innate immunity, as well as autoimmunity, inflammation, and atherosclerosis. There have not been any studies assessing the effects of biologics on nAAbs in RA and AS, also in relation to vascular pathophysiology. Fifty-three anti-TNF-treated RA and AS patients were included in a 12-month follow-up study. Anti-citrate synthase (CS) and anti-topoisomerase I fragment 4 (TOPO-F4) IgM and IgG levels were determined by ELISA. Ultrasonography was performed to assess brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV). Other variables were also evaluated at baseline and 6 and 12 months after treatment initiation. Anti-TNF therapy improved FMD in RA and PWV in AS and stabilized ccIMT. TNF inhibition increased anti-CS IgM and IgG, and possibly also anti-TOPO-F4 IgG levels. Various correlation analyses revealed that nAAbs might be independently involved in autoimmunity as well as changes in inflammation and vascular pathology over time in biologic-treated patients (

Indexed as

Arthritis, RheumatoidAtherosclerosisBiological ProductsSpondylitis, AnkylosingAutoantibodiesCarotid Intima-Media ThicknessFollow-Up StudiesHumansImmunoglobulin GImmunoglobulin MInflammationTumor Necrosis Factor InhibitorsAutoantibodiesBiological ProductsImmunoglobulin GImmunoglobulin MTumor Necrosis Factor Inhibitorsankylosing spondylitisanti-TNF therapybiomarkersnatural autoantibodiesrheumatoid arthritis

Identifiers

PMID38542402
PMCPMC10970856
OpenAlexW4392962115

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.